|Bid||111.52 x 1300|
|Ask||112.45 x 800|
|Day's Range||109.90 - 112.15|
|52 Week Range||81.66 - 112.15|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||34.36|
|Earnings Date||Nov 19, 2019|
|Forward Dividend & Yield||2.16 (1.98%)|
|1y Target Est||118.48|
This weekend's Barron's cover story explains how to generate income in retirement. Other featured articles discuss big tech's take on banking and retailers that have been left behind. Also, the prospects ...
Many patients with severe but stable heart disease who routinely undergo invasive procedures to clear and prop open clogged arteries would do as well by just taking medications and making lifestyle changes, U.S. researchers reported on Saturday. The $100 million government-backed study, presented at the American Heart Association (AHA) meeting in Philadelphia, is the largest yet to look at whether procedures to restore normal blood flow in patients with stable heart disease offers an added benefit over more conservative treatment with aspirin, cholesterol-lowering drugs and other measures. At least two prior studies determined that artery-clearing and stenting or bypass surgery in addition to medical treatment does not significantly lower the risk of heart attacks or death compared with non-invasive medical approaches alone.
The Medtronic 2019 Integrated Performance Report Shares Progress on Pay Equity, Diversity in Management Roles, Access to Healthcare, Environmental Performance, UN Sustainable.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.
DUBLIN, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra™ Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart, called atrioventricular (AV) block. The results from the MARVEL 2 study will be presented Nov. 16 during a Featured Science session at American Heart Association 2019, the AHA Scientific Sessions and were published today in JACC: Clinical Electrophysiology.
“We have 22 presenting companies on the agenda, and they are the stars of the show. It is the place for startups and the entrepreneurs who run them, the investors that support them … and the strategic partners that hopefully buy them.”
Minnesota’s business leaders were by a large margin backing U.S. Sen. Amy Klobuchar (D-Minn.) in the early stages of 2020 presidential election.
DUBLIN and LAS VEGAS, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT™ Admiral™ drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Professor Thomas Zeller, M.D., director of the Department of Angiology at Universitaets-Herzzentrum, Freiburg-Bad Krozingen, Germany, presented the new, four-year results from the full clinical cohort of the IN.PACT Global Study. The results are the first four-year, real-world, fully adjudicated DCB data to be presented in a scientific congress.
Medtronic plc (MDT) announced today that it will report financial results for the second quarter of fiscal year 2020 on Tuesday, November 19, 2019. The news release will include summary financial information for the company’s second quarter of fiscal year 2020, which ended on Friday, October 25, 2019. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its second quarter of fiscal year 2020.
Medtronic plc (MDT) today announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and the launch of the Valiant Navion™ thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). The news marks the third major geographical launch of the Valiant Navion, following FDA and CE Mark approvals in late 2018. The low-profile Valiant Navion system is built to further improve upon the performance of the market-leading Valiant™ Captivia™ thoracic stent graft system, which has treated more than 100,000 patients globally, while also broadening patient applicability.
Medtronic plc (MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) therapy at the Samsung Developers Conference in San Jose, Calif. The new programmer – which received U.S. Food and Drug Administration (FDA) approval on July 3, 2019 – leverages a user-friendly, custom-configured Samsung mobile device which allows patients to manage their therapy more simply and discreetly. To date, more than 150,000 patients have been implanted with Medtronic DBS devices for management of Parkinson’s symptoms and other conditions. “It is important for patients to have access to advanced technology for user-friendly therapy management at home,” says Sandeep Thakkar, D.O., neurologist and movement disorder specialist at Hoag’s Pickup Family Neurosciences Institute.
Tamarack Capital Management was founded by Justin John Ferayorni, who remained the fund’s Chief Investment Officer and Portfolio Manager. Mr. Ferayorni holds A.B. degree in Chemistry from Princeton University, as well as Chartered Financial Analyst designation. Prior to founding Tamarack Capital Management, he worked as Healthcare Analyst and Portfolio Manager. He also held a position of […]